25 November 2025
25 November 2025
Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.
While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the preventive Alzheimer’s setting.
The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.
An FDA officer explains the agency’s compliance requirements for importing pharmaceuticals and biologics and processes.
The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.
At the 13th Annual Veeva Commercial Summit Europe, experts touted the benefits of AI but stressed the importance of data and future-proofing in its long-term success.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
